NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis $4.54 +0.48 (+11.82%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$4.49 -0.05 (-1.15%) As of 10/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Myriad Genetics Stock (NASDAQ:MYGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Myriad Genetics alerts:Sign Up Key Stats Today's Range$4.16▼$4.5950-Day Range$2.86▼$5.4552-Week Range$2.74▼$8.59Volume2.27 million shsAverage Volume2.04 million shsMarket Capitalization$434.25 millionP/E RatioN/ADividend YieldN/APrice Target$3.93Consensus RatingReduce Company Overview Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests designed to help healthcare professionals assess disease risk, guide treatment decisions and support patient care. The company serves physicians, hospitals, health systems, biopharmaceutical companies and patients, with a focus on areas including oncology, women’s health and mental health. Its portfolio includes hereditary cancer testing, such as the MyRisk Hereditary Cancer test; tumor profiling and companion diagnostic services used to help inform cancer treatment; prenatal and carrier screening tests, including Prequel and Foresight; and pharmacogenomic testing, including GeneSight, which is intended to help clinicians evaluate how a patient may respond to certain psychiatric medications. Myriad also offers testing and services for other inherited and acquired health conditions. Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics has built its business around applying genetic information to personalized medicine. The company primarily serves the United States and also provides products and services through international markets and commercial partnerships, subject to local regulatory and reimbursement requirements.AI Generated. May Contain Errors. Read More Myriad Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreMYGN MarketRank™: Myriad Genetics scored higher than 21% of companies evaluated by MarketBeat, and ranked 792nd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingMyriad Genetics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 3 sell ratings.Downside RiskMyriad Genetics has a consensus price target of $3.93, representing about 13.4% downside from its current price of $4.54.Amount of Analyst CoverageMyriad Genetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Myriad Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.99) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.96% of the float of Myriad Genetics has been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 4.27.Change versus previous monthShort interest in Myriad Genetics has recently increased by 19.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.61 News SentimentMyriad Genetics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Myriad Genetics this week, compared to 4 articles on an average week.Search Interest1 people have searched for MYGN on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders1.90% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYGN Stock News HeadlinesMyriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split TargetsOctober 4 at 6:01 AM | finance.yahoo.comMyriad Genetics (NASDAQ:MYGN) vs. Applied Dna Sciences (NASDAQ:BNBX) Head-To-Head ComparisonSeptember 30, 2026 | americanbankingnews.comA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One executive order could change that — potentially triggering the largest wealth transfer into gold in modern American history. The last time the U.S. faced this combination of inflation, debt, and monetary pressure, gold climbed 2,300% in the 1970s. Reagan Gold Group's free 2026 Gold Guide breaks down what investors need to know now.October 4 at 1:00 AM | Reagan Gold Group (Ad)Comparing Vertex Pharmaceuticals (NASDAQ:VRTX) and Myriad Genetics (NASDAQ:MYGN)September 28, 2026 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Reduce" by BrokeragesSeptember 23, 2026 | americanbankingnews.comMyriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance ResetSeptember 18, 2026 | finance.yahoo.comMyriad Genetics Names Sikri Commercial EVP; Reaffirms 2026 GuidanceSeptember 16, 2026 | rttnews.comMyriad Genetics Appoints Vishal Sikri Executive Vice President - CommercialSeptember 16, 2026 | globenewswire.comSee More Headlines MYGN Stock Analysis - Frequently Asked Questions How have MYGN shares performed this year? Myriad Genetics' stock was trading at $6.15 on January 1st, 2026. Since then, MYGN shares have decreased by 26.2% and is now trading at $4.54. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.19. The business's quarterly revenue was down 10.5% compared to the same quarter last year. Read the conference call transcript. Does Myriad Genetics have any subsidiaries? Myriad Genetics subsidiaries include Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX). Company Calendar Last Earnings7/30/2026Today10/04/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 6 days, MYGN's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Price Target for Myriad Genetics$3.93 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside-13.4%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$365.90 million Net Margins-13.96% Pretax Margin-13.86% Return on Equity-16.09% Return on Assets-8.10% Debt Debt-to-Equity Ratio0.40 Current Ratio2.21 Quick Ratio1.98 Sales & Book Value Annual Sales$824.50 million Price / Sales0.53 Cash Flow$3.75 per share Price / Cash Flow1.21 Book Value$3.95 per share Price / Book1.15Miscellaneous Outstanding Shares95,650,000Free Float93,833,000Market Cap$434.25 million OptionableOptionable Beta1.64 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MYGN) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
